GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

A solid showing for HIV drugs sold by majority-owned ViiV Healthcare and speciality medicines like cancer therapies Zejula ...

Clover announces positive clinical data for RSV vaccine candidate SCB-1019 compared head-to-head versus GSK’s Arexvy: Shanghai Wednesday, October 30, 2024, 17:00 Hrs [IST] Clove ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...